Skip to main content
  • Contact Us
  • Subscriber Sign In
Evaluate Logo

navigation

  • What We Do
    • Commercial Intelligence
    • Products
      • Evaluate Pharma
      • Evaluate Omnium
      • Evaluate Medtech
      • Evaluate Epi
      • Japan Drug Forecasts
      • Europe Drug Forecasts
      • CDMO Intelligence
    • Pharma Consulting & Analytics
      • Pharma Consulting & Analytics
      • Data Feeds
    • Evaluate Vantage
      • News
      • Analysis
      • Policy & Pricing
      • Insights
      • Events
      • Medtech
      • Therapy Areas
    • Evaluate for Biotech
  • How We Can Help You
    • Pharma and Biotech
    • Financial Services
    • Management Consultancies
    • Service Providers
    • Customer Testimonials
  • Thought Leadership
    • Multimedia
    • Blog
  • About Us
    • Press Releases
    • Media Coverage
    • Executive Team
    • Vision & History
  • Contact Us
  • Sign Up for Evaluate Vantage
  • Talent
  • Subscriber Sign In

 

Vantage logo

Vantage

  • News
    • Snippets
    • Deals
    • Trial results
    • Patents and litigation
    • Corporate strategy
  • Analysis
    • Interviews
    • Spotlight
    • Vantage points
    • Vantage views
  • Insights
    • M&A
    • IPO
    • NME approvals
    • Quarterly shareprice performance
    • Venture financing
    • Vantage data points
    • Other data
  • Events
    • Company events
    • Conferences
    • Upcoming events
  • Medtech
  • Therapy Areas

Breadcrumb

  1. Home
  2. Vantage
  3. Pharmaceutical Companies
  4. Neurosearch

Evaluate

August 03, 2016

Therapy focus – One step forward but two steps back in Huntington’s

February 21, 2014

Glimmers of hope in Huntington's must not be overstated

Vantage logo
May 22, 2013

Search continues for biomarkers to aid Huntington’s research

Vantage logo
April 11, 2013

Therapeutic focus – Two steps back for Huntington’s disease

Vantage logo
March 22, 2013

Genmab basks in Nordic glory

Vantage logo
July 04, 2012

Obesity turnaround drives small cap gainers in H1

Vantage logo
March 20, 2012

Therapeutic focus - Hopes fading for nicotinic receptors as Astra pill flunks

Vantage logo
December 02, 2011

Scandinavian biotech hit particularly hard in bad year for sector

Vantage logo
October 04, 2011

Pharmasset continues to lead small cap gainers so far in 2011

Vantage logo
August 25, 2011

Most valuable unpartnered pipeline assets – what's hot and what's not

Vantage logo
April 13, 2011

EP Vantage Interview - NeuroSearch seeking path forward for Huntexil

  • Load More

Latest Reports

July 27, 2023

H1 Round Up: The haves and the have-nots

July 21, 2023

ADA/EASL eBook

View more...

Editor's Picks

Vantage logo
July 03, 2023

Astrazeneca and Daiichi’s big reveal disappoints

Vantage logo
July 13, 2023

Pharma finds a way to gain weight

Vantage logo
July 03, 2023

Protagonist investors flake as psoriasis pill disappoints

Vantage logo
June 29, 2023

Approaching datasets for big pharma

Vantage logo
June 27, 2023

Nkarta goes back to basics

Open modal

Evaluate Logo

Evaluate HQ
44-(0)20-7377-0800

Evaluate Americas
+1-617-573-9450

Evaluate APAC
+81-80-1164-4754

Footer menu

  • Terms and conditions
  • Privacy Policies
  • Cookie Policy
  • Modern Slavery Statement

© Copyright 2023 Evaluate Ltd.

Sign up